Acurx Pharmaceuticals

ACXP · NASDAQ

$1.14+$0.00 (+0.00%)TodayMarket closed · Oct 21, 5:30 AM ET

Prev close $1.14

ACXP analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $17.34 (+1421.1% upside)

Low: $10.10
Now: $1.14
High: $32.55

Upgrades and downgrades

The latest rating actions, newest first

ACXP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 29, 2026	Maintains	Buy	$31.00	17%

The case for and against

Updated Mar 20, 2026

Bull case

Acurx Pharmaceuticals Inc. has received encouraging feedback from the FDA and EMA regarding its antibiotic candidate, ibezapolstat (IBZ), which has positioned the company favorably for its upcoming Phase 3 trial in adult populations. The notable antimicrobial activity and established favorable safety profile observed in patients amplify the potential for successful clinical outcomes. Additionally, the positive opinion on the company's Pediatric Investigation Plan (PIP) for the use of IBZ in children further enhances the growth prospects and market potential of Acurx's developing therapies.

Bear case

Acurx Pharmaceuticals Inc. faces significant financial hurdles due to its clinical stage status, which limits immediate revenue generation and increases the reliance on external funding to support ongoing research and development efforts. The company's focus on a niche segment of antibiotic development may heighten investor skepticism, as the competitive landscape in the biopharmaceutical industry is characterized by high failure rates and substantial regulatory challenges. Furthermore, persistent valuation concerns, compounded by operational risks and the potential for delayed product timelines, contribute to a negative outlook on the company's long-term financial viability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.